Cat. No. 1524
Chemical Name: (4S,5R)-N-(4-Bromophenyl)-3-oxo-4,5
Biological ActivitySelective CCK2 receptor antagonist (IC50 values are 16 and > 30,000 nM for CCK2 and CCK1 respectively). Displays anxiolytic and antipsychotic properties in vivo.
Licensing InformationSold with the permission of Eli Lilly and Company
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Helton et al (1996) Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol.Biochem.Behav. 53 493. PMID: 8866946.
Rasmussen (1994) CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons. Ann.N.Y.Acad.Sci. 713 300. PMID: 8185172.
Rasmussen et al (1992) Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons. J.Pharmacol.Exp.Ther. 264 480.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for LY 288513 include:
Wen et al (2012) Cholecystokinin receptor-1 mediates the inhibitory effects of exogenous cholecystokinin octapeptide on cellular morphine dependence. Front Endocrinol (Lausanne) 13 63. PMID: 22682150.
Do you know of a great paper that uses LY 288513 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: LY 288513, supplier, Selective, CCK2, antagonists, Cholecystokinin2, Receptors, LY288513, Tocris Bioscience, CCK2 Receptor Antagonist products
Find multiple products by catalog number
December 3 - 7, 2016
San Francisco, CA,